UBS Group’s Altimmune ALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.79M | Buy |
904,768
+262,720
| +41% | +$1.12M | ﹤0.01% | 4664 |
|
|
2025
Q4 | $2.32M | Sell |
642,048
-789
| -0.1% | -$3.44K | ﹤0.01% | 4839 |
|
|
2025
Q3 | $2.42M | Sell |
642,837
-244,081
| -28% | -$942K | ﹤0.01% | 4782 |
|
|
2025
Q2 | $3.43M | Buy |
886,918
+98,753
| +13% | +$534K | ﹤0.01% | 4260 |
|
|
2025
Q1 | $3.94M | Buy |
788,165
+68,610
| +10% | +$435K | ﹤0.01% | 4029 |
|
|
2024
Q4 | $5.19M | Buy |
719,555
+437,100
| +155% | +$3.34M | ﹤0.01% | 3809 |
|
|
2024
Q3 | $1.73M | Buy |
282,455
+122,854
| +77% | +$832K | ﹤0.01% | 4138 |
|
|
2024
Q2 | $1.06M | Sell |
159,601
-330,400
| -67% | -$2.44M | ﹤0.01% | 4372 |
|
|
2024
Q1 | $4.99M | Buy |
490,001
+431,741
| +741% | +$4.39M | ﹤0.01% | 2977 |
|
|
2023
Q4 | $655K | Buy |
58,260
+34,004
| +140% | +$142K | ﹤0.01% | 4864 |
|
|
2023
Q3 | $63.1K | Buy |
24,256
+5,694
| +31% | +$16.3K | ﹤0.01% | 6149 |
|
|
2023
Q2 | $65.5K | Sell |
18,562
-143,636
| -89% | -$645K | ﹤0.01% | 6313 |
|
|
2023
Q1 | $684K | Sell |
162,198
-220,871
| -58% | -$2.62M | ﹤0.01% | 4442 |
|
|
2022
Q4 | $6.3M | Buy |
383,069
+326,792
| +581% | +$3.67M | ﹤0.01% | 2272 |
|
|
2022
Q3 | $718K | Buy |
56,277
+55,769
| +10,978% | +$823K | ﹤0.01% | 4032 |
|
|
2022
Q2 | $6K | Sell |
508
-1,500
| -75% | -$9.25K | ﹤0.01% | 8648 |
|
|
2022
Q1 | $12K | Sell |
2,008
-172,840
| -99% | -$1.27M | ﹤0.01% | 8153 |
|
|
2021
Q4 | $1.6M | Buy |
174,848
+73,106
| +72% | +$777K | ﹤0.01% | 3941 |
|
|
2021
Q3 | $1.15M | Buy |
101,742
+67,557
| +198% | +$822K | ﹤0.01% | 4069 |
|
|
2021
Q2 | $337K | Sell |
34,185
-57,642
| -63% | -$788K | ﹤0.01% | 5005 |
|
|
2021
Q1 | $1.3M | Sell |
91,827
-1,309,863
| -93% | -$21.2M | ﹤0.01% | 3991 |
|
|
2020
Q4 | $15.8M | Buy |
1,401,690
+1,400,483
| +116,030% | +$16.5M | 0.01% | 1503 |
|
|
2020
Q3 | $16K | Sell |
1,207
-36,438
| -97% | -$728K | ﹤0.01% | 6464 |
|
|
2020
Q2 | $403K | Buy |
37,645
+37,145
| +7,429% | +$204K | ﹤0.01% | 4319 |
|
|
2020
Q1 | $2K | Sell |
500
-2,631
| -84% | -$6.05K | ﹤0.01% | 7592 |
|
|
2019
Q4 | $6K | Buy |
3,131
+2,700
| +626% | +$4.99K | ﹤0.01% | 7495 |
|
|
2019
Q3 | $1K | Sell |
431
-992
| -70% | -$2.2K | ﹤0.01% | 7810 |
|
|
2019
Q2 | $3K | Buy |
+1,423
| New | +$3.81K | ﹤0.01% | 7517 |
|
|
2019
Q1 | – | Sell |
-631
| Closed | -$1K | – | 7696 |
|
|
2018
Q4 | $1K | Buy |
+631
| New | +$2.23K | ﹤0.01% | 7874 |
|
|
2018
Q3 | – | Sell |
-593
| Closed | -$8K | – | 7949 |
|
|
2018
Q2 | $8K | Buy |
+593
| New | +$11.7K | ﹤0.01% | 7245 |
|
|
2018
Q1 | – | Sell |
-444
| Closed | -$22.3K | – | 7776 |
|
|
2017
Q4 | $27K | Buy |
444
+238
| +116% | +$15.2K | ﹤0.01% | 6320 |
|
|
2017
Q3 | $14K | Buy |
206
+74
| +56% | +$5.51K | ﹤0.01% | 6690 |
|
|
2017
Q2 | $13K | Buy |
132
+10
| +8% | +$1.66K | ﹤0.01% | 6593 |
|
|
2017
Q1 | $30K | Sell |
122
-31
| -20% | -$16.6K | ﹤0.01% | 5853 |
|
|
2016
Q4 | $149K | Buy |
153
+132
| +629% | +$118K | ﹤0.01% | 4994 |
|
|
2016
Q3 | $18K | Buy |
+21
| New | +$16.5K | ﹤0.01% | 6371 |
|
|
2016
Q2 | – | Sell |
-12
| Closed | -$7K | – | 7686 |
|
|
2016
Q1 | $7K | Buy |
12
+4
| +50% | +$2.05K | ﹤0.01% | 6835 |
|
|
2015
Q4 | $5K | Buy |
8
+7
| +700% | +$3.49K | ﹤0.01% | 7675 |
|
|
2015
Q3 | $1K | Sell |
1
-36
| -97% | -$17.1K | ﹤0.01% | 8198 |
|
|
2015
Q2 | $20K | Buy |
37
+15
| +68% | +$7.58K | ﹤0.01% | 6860 |
|
|
2015
Q1 | $11K | Sell |
22
-22
| -50% | -$11K | ﹤0.01% | 7545 |
|
|
2014
Q4 | $24K | Buy |
+44
| New | +$22.6K | ﹤0.01% | 7366 |
|
Other funds holding ALT
VCM
VPM
N
UBS Group's ALT Position: Q1 2026 in Review
UBS Group increased its Altimmune (ALT) stake by 41% in Q1 2026, buying an estimated $1.12M and bringing the position to 904,768 shares worth $2.79M. The position accounts for ﹤0.01% of the portfolio, ranked #4664.
UBS Group first reported a position in ALT in Q4 2014 and has held it in 42 quarters since. The position peaked at $15.8M in Q4 2020. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.
- UBS Group held 904,768 shares of Altimmune worth $2.79M as of Q1 2026.
- UBS Group bought 262,720 Altimmune shares in Q1 2026, an estimated $1.12M.
- Altimmune made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4664 holding.
- UBS Group first reported a position in Altimmune in Q4 2014 and has held it in 42 quarters since.
- UBS Group's Altimmune position peaked at $15.8M in Q4 2020.
- 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.